Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80

Benzinga Newsdesk www.benzinga.com Negative 53.7%

Neg 53.7% Neu 0% Pos 0%

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $95 to $80.